Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
Martin Benedikt, Harald Mangge, Faisal Aziz, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 18
Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence
Paschalis Karakasis, Dimitrios Patoulias, George Kassimis, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 27, pp. 2109-2119
Closed Access | Times Cited: 10
SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART
H C Rosen, Moman A. Mohammad, Tomas Jernberg, et al.
The Lancet Regional Health - Europe (2024) Vol. 45, pp. 101032-101032
Open Access | Times Cited: 7
Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes
Tafadzwa T J Kufazvinei, Jason Chai, Katherine A Boden, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 11, pp. 1241-1252
Open Access | Times Cited: 6
Timing of SGLT2i initiation after acute myocardial infarction
Dirk von Lewinski, Ewald Kolesnik, Faisal Aziz, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 16
Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study
Gassan Moady, Igor Yakubovich, Shaul Atar
Journal of Cardiovascular Pharmacology and Therapeutics (2024) Vol. 29
Open Access | Times Cited: 5
The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials
Sepehr Gohari, Faramarz Ismail‐Beigi, Mahsa Mahjani, et al.
BMC Endocrine Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
Rujie Zheng, Wenjuan Song, Jie Lu, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
Nicia I. Profili, Roberto Castelli, Roberto Manetti, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 720-720
Open Access
Effect of Empagliflozin on Serum Ferritin and Its Relationship With Inflammatory Markers in Prediabetic and Diabetic Patients
Mojgan Sanjari, Narges Sadeghi, Azade Ramezannezhad, et al.
Journal of Diabetes Research (2025) Vol. 2025, Iss. 1
Open Access
Myocardial Infarction
Mukesh Nandave
(2024), pp. 249-318
Closed Access | Times Cited: 3
Development of a multidimensional prediction model for long-term prognostic risk in patients with acute coronary syndromes after percutaneous coronary intervention: A retrospective observational cohort study
Bojian Wang, Yanwei Du, Pengyu Cao, et al.
PLoS ONE (2025) Vol. 20, Iss. 5, pp. e0318445-e0318445
Open Access
Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial
Caren Sourij, Abderrahim Oulhaj, Faisal Aziz, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1971-1975
Open Access | Times Cited: 2
Empagliflozin attenuates radiation-induced hematopoietic damage via NOX-4/ROS/p38 pathway
Qidong Huo, Tongpeng Yue, Wenxuan Li, et al.
Life Sciences (2024) Vol. 341, pp. 122486-122486
Closed Access | Times Cited: 2
APOB and CCL17 as mediators in the protective effect of SGLT2 inhibition against myocardial infarction: Insights from proteome-wide mendelian randomization
Lili Shi, Gen Li, Ningxin Hou, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176619-176619
Closed Access | Times Cited: 2
Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction
Bin Xiong, Li-Min He, An Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?
Paul Zimmermann, Harald Sourij, Felix Aberer, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 12, pp. 478-478
Open Access | Times Cited: 2
The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort.
Hossein Samadanifard, Zahra Barati, Amir Hossein Ghanooni, et al.
PubMed (2024) Vol. 38, pp. x-x
Closed Access
The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review
Ryaan EL‐Andari, Nicholas M. Fialka, Jimmy J.H. Kang, et al.
American Journal of Cardiovascular Drugs (2023)
Closed Access | Times Cited: 1
Can a genetic mutation associated with glycosuria teach us about the action of sodium–glucose cotransporter-2 inhibitors?
Jonathan Golledge
Cardiovascular Research (2023) Vol. 119, Iss. 14, pp. 2385-2386
Open Access
Page 1

Scroll to top